A Phase I clinical study evaluating single-ascending doses of NKTR-358 in healthy subjects.

Trial Profile

A Phase I clinical study evaluating single-ascending doses of NKTR-358 in healthy subjects.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 May 2017

At a glance

  • Drugs NKTR 358 (Primary)
  • Indications Autoimmune disorders
  • Focus Adverse reactions
  • Most Recent Events

    • 09 May 2017 According to a Nektar Therapeutics media release, company plan to report the results from this trial at a medical meeting in the second half of 2017.
    • 30 Mar 2017 New trial record
    • 27 Mar 2017 According to a Nektar Therapeutics media release, company today announced that it has begun dosing in this clinical study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top